Neurological Sciences

, Volume 23, Issue 2, pp s53-s54

Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease

  • G. ArabiaAffiliated withInstitute of Neurology, University of Catanzaro, Policlinico Mater Domini, Via T. Campanella, I-88100 Catanzaro, Italy
  • , M. ZappiaAffiliated withInstitute of Neurology, University of Catanzaro, Policlinico Mater Domini, Via T. Campanella, I-88100 Catanzaro, Italy
  • , D. BoscoAffiliated withInstitute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • , L. CrescibeneAffiliated withInstitute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • , A. BagalàAffiliated withInstitute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • , L. BastoneAffiliated withInstitute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • , M. CaraccioloAffiliated withInstitute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • , M. ScornaienghiAffiliated withInstitute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • , A. QuattroneAffiliated withInstitute of Neurology, University of Catanzaro, Policlinico Mater Domini, Via T. Campanella, I-88100 Catanzaro, Italy

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract.

We conducted a pharmacokinetic study in 164 patients with sporadic Parkinson's disease (PD) to address the relationship between body weight and levodopa pharmacokinetics. Patients underwent an oral acute levodopa test with 250 mg levodopa and pharmacokinetic variables were further assessed. Plasmatic levodopa area under the curve (AUC-l) and body weight were significantly and inversely correlated. Women were significantly lighter and more dyskinetic than men, and had greater AUC-l values. Our data suggest that during long-term treatment, lighter PD patients, especially women, may receive a greater cumulative dosage of levodopa per kilogram of body weight. This could explain gender differences for the development of levodopa-induced peak-dose dyskinesias observed during the course of the disease.